{
    "clinical_study": {
        "@rank": "164971", 
        "arm_group": [
            {
                "arm_group_label": "Continuous Therapy", 
                "arm_group_type": "Other", 
                "description": "TOBI\u2122 Podhaler\u2122 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle Cayston 75 mg inhaled three times daily.  Repeat cycle."
            }, 
            {
                "arm_group_label": "Cyclic therapy", 
                "arm_group_type": "Other", 
                "description": "TOBI\u2122 Podhaler\u2122 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used.  Repeat cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to characterize bacterial diversity and richness in the sputum\n      of cystic fibrosis patients treated with every-other-month TOBI\u2122 Podhaler\u2122 and continuous\n      alternating therapy with TOBI\u2122 Podhaler and Cayston\u2122."
        }, 
        "brief_title": "Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis", 
                "Pulmonary Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of cystic fibrosis confirmed by mutation analysis of the cystic fibrosis\n             transmembrane conductance regulator gene\n\n          -  Sputum or throat swab culture positive for Pseudomonas aeruginosa at or within 6\n             months of enrollment\n\n          -  Age \u226518 years\n\n          -  Forced expiratory volume in one second (FEV1) 25-80 percent-predicted\n\n        Exclusion Criteria:\n\n          -  Age <18 years\n\n          -  Inability to routinely expectorate sputum without induction by hypertonic saline\n\n          -  Inability to provide or withdrawal of written informed consent\n\n          -  History of aminoglycoside sensitivity or adverse reaction to inhaled antibiotics\n\n          -  Serum creatinine \u2265 2.0 mg/dl\n\n          -  Serum blood urea nitrogen (BUN) \u226540 mg/dl\n\n          -  Pregnancy or lactating at screening\n\n          -  History of systemic intravenous anti-Pseudomonal antibiotics within 28 days of\n             enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113397", 
            "org_study_id": "D14010", 
            "secondary_id": "CTBM100DUS02T"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Continuous Therapy", 
                    "Cyclic therapy"
                ], 
                "intervention_name": "TOBI\u2122 Podhaler\u2122 112 mg inhaled twice daily", 
                "intervention_type": "Drug", 
                "other_name": "Tobramycin inhalation powder"
            }, 
            {
                "arm_group_label": "Continuous Therapy", 
                "intervention_name": "Cayston 75 mg inhaled three times daily", 
                "intervention_type": "Drug", 
                "other_name": "Aztreonam lysine solution for inhalation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Aztreonam", 
                "Tobramycin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cystic fibrosis", 
            "Microbiome", 
            "Sputum", 
            "Tobramycin", 
            "Aztreonam"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "jennifer.e.helm@hitchcock.org", 
                "last_name": "Jennifer E. Helm, B.S.", 
                "phone": "603-650-8178"
            }, 
            "contact_backup": {
                "email": "lisa.a.moulton@hitchcock.org", 
                "last_name": "Lisa A Moulton, R.N.", 
                "phone": "(603) 650-8178"
            }, 
            "facility": {
                "address": {
                    "city": "Lebanon", 
                    "country": "United States", 
                    "state": "New Hampshire", 
                    "zip": "03756"
                }, 
                "name": "Dartmouth-Hitchcock Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Alex H Gifford, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Alix Ashare, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "H. Worth Parker, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Richard I Enelow, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Evaluation of Bacterial Diversity and Richness in the Cystic Fibrosis Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI\u2122 Podhaler\u2122) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI\u2122 Podhaler\u2122) and Aztreonam Lysine for Inhalation (Cayston\u2122)", 
        "overall_contact": {
            "email": "alex.h.gifford@hitchcock.org", 
            "last_name": "Alex H Gifford, M.D.", 
            "phone": "(603) 650-5533"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary estimate in our study is the mean effects of Continuous Alternating Therapy compared to Cyclic therapy on Simpson Diversity Index (SDI) averaged at month 6", 
            "measure": "Simpson Diversity Index", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "22753064", 
                "citation": "Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, Morrison HG, Paster BJ, O'Toole GA. Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol. 2012 Sep;194(17):4709-17. doi: 10.1128/JB.00566-12. Epub 2012 Jun 29."
            }, 
            {
                "PMID": "24451123", 
                "citation": "Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, Sogin ML, O'Toole GA. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome. 2013 Nov 1;1(1):27. doi: 10.1186/2049-2618-1-27."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113397"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dartmouth-Hitchcock Medical Center", 
            "investigator_full_name": "Alex H. Gifford", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Using 454 pyrosequencing and quantitative polymerase chain reaction (qPCR) techniques, the relative abundance of various bacterial genera will be determined.", 
            "measure": "Bacterial Relative Abundance", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Dartmouth-Hitchcock Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Dartmouth-Hitchcock Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}